Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 12/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19151155 | 0.98 | LMNA (0.42) | LMNAMEN1KMT2AP2RX7BRD4 | |
| SCHEMBL15427281 | 0.94 | MEN1 (0.41) | LMNAMEN1KMT2AP2RX7BRD4 | |
| SCHEMBL19151096 | 0.90 | MEN1 (0.44) | LMNAMEN1KMT2AP2RX7BRD4 | |
| SCHEMBL23052290 | 0.82 | LMNA (0.46) | LMNAMEN1KMT2A | |
| SCHEMBL19116334 | 0.81 | TP53 (0.41) | LMNAP2RX7BRD4 | |
| SCHEMBL31616170 | 0.80 | ALDH1A1 (0.40) | LMNAP2RX7 | |
| SCHEMBL13013428 | 0.79 | P2RX7 (0.41) | P2RX7BRD4 | |
| SCHEMBL19116506 | 0.78 | SMN1; SMN2 (0.42) | LMNAMEN1KMT2AP2RX7BRD4 | |
| SCHEMBL15621584 | 0.78 | LMNA (0.56) | LMNAP2RX7BRD4 | |
| SCHEMBL22449838 | 0.78 | ALDH1A1 (0.41) | LMNAP2RX7BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402785-B1 | 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| WO-2017121649-A1 | 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-07-20 | — | — | WO | disclosed |
| US-9056862-B2 | Thioxothiazolidine derivative having Ras function inhibitory effect | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2015-06-16 | — | — | US | disclosed |
| US-9056862-B2 | Thioxothiazolidine derivative having Ras function inhibitory effect | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2015-06-16 | — | — | US | disclosed |
| US-20140194412-A1 | THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT | KNC LABORATORIES CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20140194412-A1 | THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT | KNC LABORATORIES CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194412-A1 | THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT | KRAS, NRAS, RASSF5 | LMNA 4732/4885MEN1 762/4885KMT2A 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.